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LETTER TO THE EDITOR
Meta-analysis of chemotherapy in head and neck cancer: individual
patient data vs literature data
Sir - Munro (1995) should be thanked for updating the
meta-analysis on the role of chemotherapy in head and neck
cancer performed by Stell (1992) and for his well-conducted
sensitivity analysis. In his meta-analysis, based on the
literature, he identified 54 eligible trials published between
January 1963 and December 1993. In the ongoing meta-
analysis of chemotherapy in head and neck cancer (MACH-
NC), based on updated individual patient data, we have
identified 70 eligible trials (list available on request) with
accrual between January 1965 and December 1993. The com-
parison of both studies provides us with an opportunity to
discuss the advantages of the two types of meta-analyses.
Munro identified 45 out of 70 trials in MACH-NC. How-
ever, nine additional trials that were eligible in his study were
excluded from MACH-NC: one trial on nasopharynx car-
cinoma; one trial on maxillary sinus carcinoma; three old
trials, for which accrual started before 1965; one trial com-
paring chemotherapy with radiotherapy; and three trials,
each generating two separate publications, one of them con-
cerning a subgroup analysis, were considered by Munro as
separate trials whereas in fact they concerned one and the
same trial. Our study retained only the publication with the
largest population. The analysis performed by Munro has the
following shortcomings. The main analysis included only 48
of 54 trials (7443 patients) because survival rates were not
available in the publication of six trials. It mixed up survival
rates ranging from 2 to 5 years according to the trials. The
analysis included the results of two trials twice, once for the
overall populations and once for the subgroups (Munro's
references 25 and 26) as noted above, and also included two
trials on organ preservation. The aim of such trials is to
avoid mutilating surgery when chemotherapy is used without
compromising survival and not to test whether chemotherapy
increases survival.
Therefore, 25 trials were identified in the MACH-NC
study and not in Munro's study, including 11 trials published
as full papers before 1994; nine trials published as abstracts
including eight abstracts of the American Society of Clinical
Oncology, - four of which were published in 1994; and five
unpublished trials. With the help of investigators joining the
MACH-NC Collaborative Group, we hope not only to
update the follow-up and recover the data concerning the
patients excluded after the randomisation of the 70 identified
trials, which have included 10422 patients, but also to dis-
cover new trials. Then it will be possible to perform a
survival analysis (log-rank test adjusted by trial) of all
patients ever randomised (intent-to-treat analysis). We are
currently exploring the feasibility of including old trials
(before 1965) and nasopharynx trials. In MACH-NC, the
four identified organ preservation trials, like the nasopharynx
trials, will be analysed separately. This meta-analysis will also
allow us to study disease-free survival and interactions
between prognostic factors and the treatment effect. The site
of tumour, TNM (or stage), age and sex will be collected for
each patient. Such analyses were not possible in the meta-
analysis based on the literature. Furtherrnore, the quality of
the randomisation process and of the follow-up could be
checked when using individual data. Thus, the advantages of
the meta-analysis based on individual data are not limited to
the possibility ofperforming survival analysis (Munro, 1995).
Its main advantages are to obtain a more reliable estimation
of the treatment effect and a more detailed analysis of trial
data than meta-analyses based on the literature (Pignon and
Arriagada 1993; Stewart and Parmar 1993). As pointed out
by Munro, meta-analyses based on individual data take time,
approximately 3 years in our experience (Pignon et al., 1992).
Hopefully, the results of MACH-NC will be available in
early 1997 and their comparison with those of Munro's study
should be very interesting.
Yours etc,
JP Pignon
J Bourhis
C Domenge on behalf of the MACH-NC Secretariat
Departement de Biostatistique et d'Epidemiologie
Institut Gustave-Roussy
94805 Villejuif Cedex
France
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